
    
      64 participants were randomized, 63 received at least one dose of the study drug, and 62
      participants were analyzed for injection site-related pain. 63 participants were analyzed for
      other safety analyses. Two participants, who were randomized to the Current formulation
      adalimumab/New formulation of adalimumab arm of the study were excluded from the analysis of
      injection site-related pain. One participant received one dose of study drug and discontinued
      because of an adverse event, while the other discontinued before receiving any study drug.
    
  